AusperBio Therapeutics, Inc. Completes USD 73 Million Series B Financing

AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together known as AusperBio), a clinical-stage biotech company aiming to advance targeted oligonucleotide therapies for chronic hepatitis B (CHB), have completed a successful USD 73 million Series B financing.

This funding round was primarily led by HanKang Capital, and saw contributions from Sherpa Capital, CDH Investments, and a strategic investor, in addition to continued support from existing investors Qiming Venture Partners, InnoPinnacle Fund, and YuanBio Venture Capital. The recent financing round builds on the company's Series A funding in July, underscoring sustained investor confidence in its unique platform and strategic vision.

The proceeds will fund the continued Phase 2 development of AHB-137, AusperBio's lead investigational therapy, supporting both clinical studies in China and global trials, as well as the development of commercial-scale manufacturing processes. The funding will also facilitate the expansion of the company's therapeutic pipeline and operational capabilities to drive sustained growth.